Skip to content

Supplier News

Dr. Reddy’s makes foray into OTC health arena

Dr. Reddy’s makes foray into OTC health arena

Dr. Reddy’s Laboratories Ltd. has acquired six over-the-counter health product brands from Ducere Pharma LLC. Financial terms of the agreement weren’t disclosed. India-based Dr. Reddy’s, which has its U.S. office in Princeton, N.J.

Bausch + Lomb wins Walmart award

Bausch + Lomb wins Walmart award

Bausch + Lomb, a leading global supplier of ophthalmic pharmaceuticals, contact lenses, lens care products, and ophthalmic surgical devices and instruments , announced Monday that Walmart has presented the company with its 2015 U.S. Supplier of the Year Award in Consumables and Health & Wellness.

Mylan releases generic Doryx DR tablets

Mylan releases generic Doryx DR tablets

Mylan N.V. has launched doxycycline hyclate delayed-release tablets (200 mg), an antibiotic, in the United States. Mylan said its doxycycline product is a generic version of Doryx 200-mg delayed-release tablets from Mayne Pharma.

FDgard medical food hits shelves at Walgreens, CVS

FDgard medical food hits shelves at Walgreens, CVS

IM HealthScience (IMH) has launched FDgard, a nonprescription medical food for the dietary management of functional dyspepsia (FD), or persistent or recurring indigestion. IMH said Monday that FDgard is now available in the digestive aisle at most CVS/pharmacy and Walgreens stores nationwide.

Bell launches promo campaign for Jet-Alert

Bell launches promo campaign for Jet-Alert

Bell Pharmaceuticals has kicked off an eight-month promotional campaign for its Jet-Alert caffeine tablets on Sirius XM radio. The company said Thursday that the marketing push also includes online advertisements, national print advertising, social media campaigns and retailer support programs.

FDA works to speed generic drug approvals

FDA works to speed generic drug approvals

Amid calls for a quicker approval process, the Food and Drug Administration last year cleared for market the most generic drug products in its history. The FDA said it approved or issued tentative approvals for more than 700 generic drugs in 2015.

Novartis realigns pharma division into two new units

Novartis realigns pharma division into two new units

Making changes to its Pharmaceuticals Division, Novartis has created two business units that will report to the chief executive officer: Novartis Pharmaceuticals and Novartis Oncology. The new units will form the Innovative Medicines Division.